ID: ALA127691

Max Phase: Preclinical

Molecular Formula: C18H16N2O3

Molecular Weight: 308.34

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  Oc1ncc(Cc2cccc(OCc3ccccc3)c2)c(O)n1

Standard InChI:  InChI=1S/C18H16N2O3/c21-17-15(11-19-18(22)20-17)9-14-7-4-8-16(10-14)23-12-13-5-2-1-3-6-13/h1-8,10-11H,9,12H2,(H2,19,20,21,22)

Standard InChI Key:  ZJQDPXONNQFKKC-UHFFFAOYSA-N

Associated Targets(Human)

Dihydropyrimidine dehydrogenase 17 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Uridine phosphorylase 1 51 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 308.34Molecular Weight (Monoisotopic): 308.1161AlogP: 3.06#Rotatable Bonds: 5
Polar Surface Area: 75.47Molecular Species: NEUTRALHBA: 5HBD: 2
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 12.20CX Basic pKa: CX LogP: 4.37CX LogD: 4.37
Aromatic Rings: 3Heavy Atoms: 23QED Weighted: 0.76Np Likeness Score: -0.45

References

1. Orr GF, Musso DL, Boswell GE, Kelley JL, Joyner SS, Davis ST, Baccanari DP..  (1995)  Inhibition of uridine phosphorylase: synthesis and structure-activity relationships of aryl-substituted 5-benzyluracils and 1-[(2-hydroxyethoxy)methyl]-5-benzyluracils.,  38  (19): [PMID:7562916] [10.1021/jm00019a015]
2. Kelley JL, Baker BR..  (1982)  Irreversible enzyme inhibitors. 202. Candidate active-site-directed irreversible inhibitors of 5-fluoro-2'-deoxyuridine phosphorylase from Walker 256 rat tumor derived from 1-benzyl-5-(3-ethoxybenzyl)uracil.,  25  (5): [PMID:6211547] [10.1021/jm00347a022]
3. Hattori K, Kohchi Y, Oikawa N, Suda H, Ura M, Ishikawa T, Miwa M, Endoh M, Eda H, Tanimura H, Kawashima A, Horii I, Ishitsuka H, Shimma N..  (2003)  Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine.,  13  (5): [PMID:12617910] [10.1016/s0960-894x(02)01082-x]

Source